Review| Volume 43, ISSUE 10, P1808-1815, October 2017

Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis



      This study aimed to evaluate the impact on overall survival following palliative surgery to remove the primary lesion in unresectable metastatic small intestinal (SI-NET) and pancreatic neuroendocrine tumours (P-NET).


      A systematic review of the literature and meta-analysis was performed. MEDLINE and Embase databases were searched to identify articles comparing patients undergoing palliative primary tumour resection without metastatectomy vs. no resection. Relevant articles were identified in accordance with PRISMA guidelines. The primary outcome was overall survival. Included studies were evaluated for heterogeneity and publication bias.


      13 studies met the inclusion criteria, of which 6 presented data suitable for meta-analysis. No randomised controlled trials were identified. Analysis of pooled multivariate hazard ratios demonstrated significantly longer overall survival in patients undergoing resection of both P-NETs (HR 0.43; 95% CI: 0.34–0.57, p < 0.001) and SI-NETs (HR 0.47; 95% CI: 0.35–0.55, p = 0.007). The increase in median survival in patients treated surgically relative to non-surgically ranged from 14 to 46 months in P-NET, and 22–112 months in SI-NET. The number needed to treat in order that one additional patient was alive at five years, ranged from 3.0 to 4.2, and 1.7 to 7.7 respectively.


      Meta-analysis demonstrates that palliative resection of primary SI-NETs and P-NETs in the setting of unresectable metastatic disease can increase survival. Although these results should be interpreted with caution due to potential selection and publication bias, the data supports consideration of surgery, particularly in patients with low tumour burdens and good functional status.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Berardi R.
        • Rinaldi S.
        • Torniai M.
        • et al.
        Gastrointestinal neuroendocrine tumors: searching the optimal treatment strategy – a literature review.
        Crit Rev Oncol Hematol. 2016; 98: 264-274
        • Massironi S.
        • Sciola V.
        • Spampatti M.P.
        • Peracchi M.
        • Conte D.
        Gastric carcinoids: between underestimation and overtreatment.
        World J Gastroenterol. 2009; 15: 2177-2183
        • Lawrence B.
        • Gustafsson B.I.
        • Chan A.
        • Svejda B.
        • Kidd M.
        • Modlin I.M.
        The epidemiology of gastroenteropancreatic neuroendocrine tumors.
        Endocrinol Metab Clin North Am. 2011; 40 (vii): 1-18
        • Rindi G.
        • Arnold R.
        • Bosman F.T.
        • et al.
        Nomenclature and classification of neuroendocrine neoplasms of the digestive system.
        in: Bosman F.T. Carneiro F. Hruban R.H. Theise N.D. WHO classification of tumours of the digestive system. IARC, Lyon2010
        • Pavel M.
        • O'Toole D.
        • Costa F.
        • et al.
        ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site.
        Neuroendocrinology. 2016; 103: 172-185
        • Sarmiento J.M.
        • Que F.G.
        • Grant C.S.
        • Thompson G.B.
        • Farnell M.B.
        • Nagorney D.M.
        Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach.
        Surgery. 2002; 132 (discussion 982–3): 976-982
        • Scigliano S.
        • Lebtahi R.
        • Maire F.
        • et al.
        Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
        Endocr Relat Cancer. 2009; 16: 977-990
        • Norton J.A.
        • Warren R.S.
        • Kelly M.G.
        • Zuraek M.B.
        • Jensen R.T.
        Aggressive surgery for metastatic liver neuroendocrine tumors.
        Surgery. 2003; 134 (discussion 1063–5): 1057-1063
        • Oberg K.
        • Knigge U.
        • Kwekkeboom D.
        • Perren A.
        ESMO guidelines working group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2012; 23: vii124-vii130
        • Bacchetti S.
        • Pasqual E.M.
        • Bertozzi S.
        • Londero A.P.
        • Risaliti A.
        Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.
        Gland Surg. 2014; 3: 243-251
        • Eriksson J.
        • Stalberg P.
        • Nilsson A.
        • et al.
        Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors.
        World J Surg. 2008; 32: 930-938
        • Niederle B.
        • Pape U.F.
        • Costa F.
        • et al.
        ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum.
        Neuroendocrinology. 2016; 103: 125-138
        • Capurso G.
        • Bettini R.
        • Rinzivillo M.
        • Boninsegna L.
        • Delle Fave G.
        • Falconi M.
        Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review.
        Neuroendocrinology. 2011; 93: 223-229
        • Du S.
        • Wang Z.
        • Sang X.
        • et al.
        Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia.
        Medicine (Baltimore). 2015; 94: e388
        • Bertani E.
        • Fazio N.
        • Botteri E.
        • et al.
        Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach.
        Surgery. 2014; 155: 607-614
        • Bettini R.
        • Mantovani W.
        • Boninsegna L.
        • et al.
        Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas.
        Dig Liver Dis. 2009; 41: 49-55
        • Falconi M.
        • Bartsch D.K.
        • Eriksson B.
        • et al.
        ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.
        Neuroendocrinology. 2012; 95: 120-134
        • Falconi M.
        • Eriksson B.
        • Kaltsas G.
        • et al.
        ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.
        Neuroendocrinology. 2016; 103: 153-171
        • Huttner F.J.
        • Schneider L.
        • Tarantino I.
        • et al.
        Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis.
        Langenbecks Arch Surg. 2015; 400: 715-723
        • Keutgen X.M.
        • Nilubol N.
        • Glanville J.
        • et al.
        Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.
        Surgery. 2016; 159: 311-318
        • Soreide O.
        • Berstad T.
        • Bakka A.
        • et al.
        Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors.
        Surgery. 1992; 111: 48-54
        • Franko J.
        • Feng W.
        • Yip L.
        • Genovese E.
        • Moser A.J.
        Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients.
        J Gastrointest Surg. 2010; 14: 541-548
        • van der Horst-Schrivers A.N.
        • Post W.J.
        • Kema I.P.
        • et al.
        Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
        Eur J Cancer. 2007; 43: 2651-2657
        • Panzuto F.
        • Nasoni S.
        • Falconi M.
        • et al.
        Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
        Endocr Relat Cancer. 2005; 12: 1083-1092
        • Capurso G.
        • Rinzivillo M.
        • Bettini R.
        • Boninsegna L.
        • Delle Fave G.
        • Falconi M.
        Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases.
        Br J Surg. 2012; 99: 1480-1486
        • Singh S.
        • Asa S.L.
        • Dey C.
        • et al.
        Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus.
        Cancer Treat Rev. 2016; 47: 32-45
        • Kunz P.L.
        • Reidy-Lagunes D.
        • Anthony L.B.
        • et al.
        Consensus guidelines for the management and treatment of neuroendocrine tumors.
        Pancreas. 2013; 42: 557-577
        • Steinmuller T.
        • Kianmanesh R.
        • Falconi M.
        • et al.
        Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary.
        Neuroendocrinology. 2008; 87: 47-62
        • Schurr P.G.
        • Strate T.
        • Rese K.
        • et al.
        Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.
        Ann Surg. 2007; 245: 273-281
        • Fendrich V.
        • Langer P.
        • Celik I.
        • et al.
        An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors.
        Ann Surg. 2006; 244 (discussion 852–3): 845-851
        • Solorzano C.C.
        • Lee J.E.
        • Pisters P.W.
        • et al.
        Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients.
        Surgery. 2001; 130: 1078-1085
        • Nguyen S.Q.
        • Angel L.P.
        • Divino C.M.
        • Schluender S.
        • Warner R.R.
        Surgery in malignant pancreatic neuroendocrine tumors.
        J Surg Oncol. 2007; 96: 397-403
        • Givi B.
        • Pommier S.J.
        • Thompson A.K.
        • Diggs B.S.
        • Pommier R.F.
        Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.
        Surgery. 2006; 140 (discussion 897–8): 891-897
        • Strosberg J.
        • Gardner N.
        • Kvols L.
        Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.
        Neuroendocrinology. 2009; 89: 471-476
        • Norlen O.
        • Stalberg P.
        • Oberg K.
        • et al.
        Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
        World J Surg. 2012; 36: 1419-1431